BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zéphir H, Gower-rousseau C, Salleron J, Simon O, Debouverie M, Le Page E, Bouhnik Y, Lebrun-frenay C, Papeix C, Vigneron B, Allez M, Prin L, Cosnes J, Vermersch P, Colombel J; for the CFSEP, GETAID and EPIMAD Groups. Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. Mult Scler 2014;20:1135-9. [DOI: 10.1177/1352458513515081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Park S, Kim TJ, Lee JY, Kim ER, Hong SN, Chang DK, Yang M, Kim S, Shin M, Kim Y. Comorbid immune-mediated diseases in inflammatory bowel disease: a nation-wide population-based study. Aliment Pharmacol Ther 2019;49:165-72. [DOI: 10.1111/apt.15076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
2 Chouhfeh L, Kavak KS, Teter BE, Weinstock-guttman B. Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients. Multiple Sclerosis and Related Disorders 2015;4:228-33. [DOI: 10.1016/j.msard.2015.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
3 Avasarala J, Guduru Z, McLouth CJ, Wilburn A, Talbert J, Sutton P, Sokola BS. Use of anti-TNF-α therapy in Crohn's disease is associated with increased incidence of multiple sclerosis. Mult Scler Relat Disord 2021;51:102942. [PMID: 33933908 DOI: 10.1016/j.msard.2021.102942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lucchini M, Giuffrè GM, Nociti V, Bianco A, De Fino C, Losavio FA, Presicce G, Calabresi P, Mirabella M. Defining the disease course of TNFα blockers-associated Multiple Sclerosis. J Neuroimmunol 2021;353:577525. [PMID: 33647875 DOI: 10.1016/j.jneuroim.2021.577525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Gandhi S, Zelman S, De Armas RE, Hemond C, Levy AN, Singh S, Korzenik J, Jangi S. Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis. Inflamm Bowel Dis 2022:izac053. [PMID: 35348692 DOI: 10.1093/ibd/izac053] [Reference Citation Analysis]
6 Attauabi M, Zhao M, Bendtsen F, Burisch J. Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases. Inflammatory Bowel Diseases 2021;27:927-39. [DOI: 10.1093/ibd/izaa167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Egeberg A, Thyssen JP, Burisch J, Colombel J. Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis—A Nationwide 20-Year Cohort Study. Journal of Investigative Dermatology 2019;139:316-23. [DOI: 10.1016/j.jid.2018.07.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
8 Burisch J, Jess T, Egeberg A. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark. Clin Gastroenterol Hepatol 2019;17:2704-2712.e3. [PMID: 30936024 DOI: 10.1016/j.cgh.2019.03.040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
9 Attauabi M, Zhao M, Bendtsen F, Burisch J. Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease. Therap Adv Gastroenterol 2021;14:17562848211004839. [PMID: 34234844 DOI: 10.1177/17562848211004839] [Reference Citation Analysis]
10 Gordon-Lipkin E, Banwell B. An update on multiple sclerosis in children: diagnosis, therapies, and prospects for the future. Expert Rev Clin Immunol 2017;13:975-89. [PMID: 28738749 DOI: 10.1080/1744666X.2017.1360135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
11 Miron G, Gurevich M, Baum S, Achiron A, Barzilai A. Psoriasis comorbidity affects multiple sclerosis neurological progression: a retrospective case - control analysis. J Eur Acad Dermatol Venereol 2017;31:2055-61. [DOI: 10.1111/jdv.14403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
12 Attauabi M, Wewer MD, Bendtsen F, Seidelin JB, Burisch J. Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis. Inflamm Bowel Dis 2022:izac003. [PMID: 35134921 DOI: 10.1093/ibd/izac003] [Reference Citation Analysis]
13 Berer K, Krishnamoorthy G. Microbial view of central nervous system autoimmunity. FEBS Lett 2014;588:4207-13. [PMID: 24746689 DOI: 10.1016/j.febslet.2014.04.007] [Cited by in Crossref: 83] [Cited by in F6Publishing: 69] [Article Influence: 10.4] [Reference Citation Analysis]
14 Lim LL, Silva DG, Lo TC, Pimentel RS, Butzkueven H, Hall AJ. Uveitis in Patients with Multiple Sclerosis in Clinical Trials of Fingolimod. Ophthalmology 2019;126:438-44. [DOI: 10.1016/j.ophtha.2018.10.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Marrie RA, Miller A, Sormani MP, Thompson A, Waubant E, Trojano M, O'Connor P, Fiest K, Reider N, Reingold S, Cohen JA; attendees of the International Workshop on Comorbidity in Multiple Sclerosis. Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology 2016;86:1446-53. [PMID: 26865523 DOI: 10.1212/WNL.0000000000002474] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 7.2] [Reference Citation Analysis]